Brain-derived neurotrophic factor gene polymorphisms: Influence on treatment response phenotypes of major depressive disorder

International Clinical Psychopharmacology

Volumn 26, Issue 1, 2011, Pages 1-10

  Kocabas, Neslihan Aygun ^a,g   Antonijevic, Irina ^h   Faghel, Carole ^a   Forray, Carlos ^h   Kasper, Siegfried ⁱ   Lecrubier, Yves ^j   Linotte, Sylvie ^b   Massat, Isabelle ^a   Mendlewicz, Julien ^d   Noro, Magali ^b   Montgomery, Stuart ^k   Oswald, Pierre ^f   Snyder, Lenore ^h   Zohar, Joseph ^l   Souery, Daniel ^c,e  

^a Chrstn Duve Intl Inst Cell M   (Belgium)

^b Fonds de la Recherche Scientifique (FNRS)   (Belgium)

^c Scientific Research FNRS   (Belgium)

^d UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^e Centre Européen de Psychologie Mé Dicale   (Belgium)

^f Psychiatric Hospital Le Chêne aux haies   (Belgium)

^g GAZI UNIVERSITY   (Turkey)

^h LUNDBECK RESEARCH USA   (United States)

ⁱ MEDICAL UNIVERSITY OF VIENNA   (Austria)

^j PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^k IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^l SHEBA MEDICAL CENTER   (Israel)

more..

Author keywords

antidepressant; brain derived neurotrophic factor; haplotype; major depressive disorder; tagging SNPs; treatment response phenotype

Indexed keywords

ANTIDEPRESSANT AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; METHIONINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VALINE;

ADULT; AGED; ARTICLE; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DNA POLYMORPHISM; DRUG RESPONSE; FEMALE; GENE LOCUS; GENETIC ASSOCIATION; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

EID: 78650814423     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/YIC.0b013e32833d18f8     Document Type: Article

References (48)

1. Adachi M, Barrot M, Autry AE, Theobald D, Monteggia LM (2008). Selective loss of brain-derived neurotrophic factor in dentate gyrus attenuates antidepres-sant efficacy. Biol Psychiatry 63:642-649.
2. Antilla S, Huuhka K, Huuhka M, Rontu R, Hurme M, Leinonen E, et al. (2007). Interaction between 5-HT1A and BDNF genotypes increases the risk of treatment-resistant depression. J Neural Transm 114:1065-1068.
3. Bath KG, Lee FS (2006). Variant BDNF (Val66Met) impact on brain structure and function. Cogn Affect Behav Neurosci 6:79-85.
4. Berton O, Krishnan V, Nestler EJ (2006). BDNF in anxiety and depression. Science 312:1598-1599.
5. Bocchio-Chiavetto C, Miniussi C, Zanardini R, Gazzoli A, Bignotti S, Specchia C, Gennarelli M (2008). 5-HTTLPR and BDNF Val66Met polymorphisms and response to rTMS treatment in drug resistant depression. Neurosci Lett 437:130-134.
6. Brunoni AR, Lopes M, Fregni F (2008). A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression. Int J Neuropsychopharmacol 11: 1169-1180.
7. Chen L, Lawlor DA, Lewis SJ, Yuan W, Abdollahi MR, Timpson NJ, et al. (2008). Genetic association study of BDNF in depression: finding from two cohort studies and a meta-analysis. Am J Med Genet B Neuropsychiatr Genet 147:814-821.
8. Choi MY, Kang RH, Lim SW, Oh KS, Lee MS (2006). Brain-derived neurotrophic factor (BDNF) gene polymorphism and citalopram response in major depressive disorders. Brain Res 1118:176-182.
9. De Luca V, Strauss J, Semeralul M, Huang S, Li PP, Warsh JJ, et al. (2008). Analysis of BDNF Val66Met allele-specific mRNA levels in bipolar disorder. Neurosci Lett 441:229-232.
10. Domschke K, Lawford B, Laje G, Berger K, Young R, Morris P, et al. (2009). Brain-derived neurotrophic factor (BDNF) gene: no major impact on antidepressant treatment response. Int J Neuropsychopharmacol 23:1-9.
11. Duncan LE, Hutchison KE, Carey G, Craighead WE (2009). Variation brain-derived neurotrophic factor (BDNF) gene is associated with the symptoms of depression. J Affect Disord 115:215-219.
12. Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A, et al. (2003). The BDNF Val66Met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 112:257-269.
13. Frodl T, Schule C, Schmitt G, Born C, Baghai T, Zill P, et al. (2007). Association of brain-derived neurotrophic factor Val66Met polymorphism with reduced hippocampal volumes in major depression. Arch Gen Psychiatry 64:410-416.
14. Gabriel S, Ziaugra L, Tabbaa D (2009). SNP genotyping using Sequenom MassARRAY iPLEX platform. Curr Protoc Hum Genet Chapter 2. Unit 2.12.
15. Gatt JM, Kuan SA, Dobson-Stone C, Paul RH, Joffe RT, Kemp AH, et al. (2008). Association between BDNF Val66Met polymorphism and trait depression is mediated via resting EEG alpha band activity. Biol Psychol 79:275-284.
16. Gratacos M, Soria V, Urretavizcaya M, Gonzalez JR, Crespo JM, Bayes M, et al. (2008). A brain-derived neurotrophic factor (BDNF) haplotype is associated with antidepressant treatment outcome in mood disorders. Pharmacoge-nomics J 8:101-112.
17. Hariri AR, Goldberg TE, Mattay VS, Kolachana BS, Callicot JH, Ehan MF, et al. (2003). Brain-derived neurotrophic factor (BDNF) Val66Met polymorphism affects human memory-related hippocampal activity and predicts memory performance. J Neurosci 23:6690-6694.
18. Hashimoto K (2007). BDNF variant linked to anxiety related behaviors. Bioassays 29:116-119.
19. Hashimoto R, Moriguchi Y, Yamashita F, Mori T, Nemoto K, Okada T, et al. (2008). Dose-dependent effect of the Val66met polymorphism of the brain-derived neurotrophic factor gene on memory-related hippocampal activity. Neurosci Lett 61:360-367.
20. Henn FA (2008). Pharmacogenetic studies of depression. Biol Psychiatry 63:1101-1102.
21. Kalueff AV, Avgustinovich DF, Kudryavtseva NN, Murphy DL, Berton O, Krishnan V, Nestler EJ (2006). BDNF in anxiety and depression. Science 312:1598-1599.
22. Kemp AH, Gordon E, Rush AJ, Williams LM (2008). Improving the prediction of the treatment response in depression: integration of clinical, cognitive, psychophysiological, neuroimaging, and genetic measures. CNS Spectr 13:1066-1086.
23. Krishnan V, Nestler EJ (2008). The molecular neurobiology of depression. Nature 455:894-902.
24. Laje G, McMahon FJ (2007). The pharmacogenetics of major depression: past, present and future. Biol Psychiatry 62:1205-1207.
25. Licinio J, Dong C, Wong ML (2009). Novel sequence variations in the brain-derived neurotrophic factor (BDNF) gene and association with major depression and antidepressant treatment response. Arch Gen Psychiatry 66:488-497.
26. Matrisciano F, Bonaccorso S, Ricciardi A, Scaccianoce S, Panaccione I, Wang L, et al. (2009). Changes in BDNF serum levels in patients with major depression disorder (MDD) after 6 months treatment with sertraline, escitalopram, or venlafaxine. J Psychiatr Res 43:247-254.
27. McMahon FJ, Buervenich S, Charney D, Lipsky R, Rush AJ, Wilson AF, et al. (2006). Variation in the gene encoding the Serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet 78:804-814.
28. Mulder RT, Joyce PR, Frampton CMA, Luty SE, Sullivan PF (2006). Six months of treatment for depression: outcome and predictors of course of illness. Am J Psychiatry 166:95-100.
29. Murray CJ, Lopez AD (2006). Evidence-based health policy-lessons from the Global Burden of Disease study. Science 274:740-743.
30. Okada T, Hashimoto R, Numakawa T, Lijima Y, Kosuga A, Tatsumi M, et al. (2006). Complex polymorphic region in the Brain-derived neurotrophic factor (BDNF) gene confers susceptibility to bipolar disorder and affects transcriptional activity. Mol Psychiatry 11:695-703.
31. Oswald P, Del-Favero J, Massat I, Souery D, Claes S, Van Broeckhoven C, Mendlewicz J (2004). Non-replication of the brain-derived neurotrophic factor (BDNF) association in bipolar affective disorder: a Belgian patient-control study. Am J Med Genet B Neuropsychiatr Genet 129:34-35.
32. Oswald P, Del-Favero J, Massat I, Souery D, Claes S, Van Broeckhoven C, Mendlewicz J (2005). No implication of brain-derived neurotrophic factor (BDNF) gene in unipolar affective disorder: evidence from Belgian first and replication patient-control studies. E Neuropsychopharmacol 15:491-495.
33. Palmer L, Cardon L (2006). Shaking the tree: mapping complex disease genes with linkage disequilibrium. Lancet 366:1223-1234.
34. Piccinni A, Debbio AD, Medda P, Bianchi C, Roncaglia I, Veltri A, et al. (2009). Plasma brain-derived neurotrophic factor (BDNF) in treatment-resistant depressed patients receiving electroconvulsive therapy. E Neuropsychophar-macol 15:491-495.
35. Pruunsild P, Kazantseva A, Aid T, Palm K, Timmusk T (2007). Dissecting the human BDNF locus: bidirectional transcription, complex splicing and multiple promoters. Genomics 90:397-406.
36. Reynolds GP (2007). The impact of pharmacogenetics on the development and use of antipsychotic drugs. Drug Discov Today 12:953-959.
37. Rybakowski JK (2008). BDNF gene: functional Val66Met polymorphism in mood disorders and schizophrenia. Pharmacogenomics 9:1589-1593.
38. Rybakowski JK, Suwalska A, Skibinska M, Dmitrzak-Weglarz M, Leszczynska-Rodziewicz A, Hauser J (2007). Response to lithium prophylaxis: interaction between serotonin transporter and BDNF genes. Am J Med Genet B Neuropsychiatr Genet 144:820-823.
39. Schumacher J, Jamra RA, Becker T, Ohlraun S, Kloop N, Binder EB, et al. (2008). Evidence for a relationship between genetic variants at the brain-derived neurotrophic factor (BDNF) locus and major depression. Biol Psychiatry 58:307-314.
40. Sen S, Duman R, Sanacora G (2008). Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatry 64:527-532.
41. Souery D, Oswald P, Massat I, Bailer U, Bollen J, Demyttenaere K, et al. (2007). Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. J Clin Psychiatry 68:1062-1070.
42. Sullivan PF (2007). Spurious genetic associations. Biol Psychiatry 61: 1121-1126.
43. Tsai SJ, Cheng CY, Yu YW, Chen TJ, Hong CJ (2003). Association study of a brain-derived neurotrophic factor genetic polymorphism and major depressive disorders, symptomatology, and antidepressant response. Am J Med Genet B Neuropsychiatr Genet 123:19-22.
44. Uher R (2008). The implications of gene-environment interactions in depression: will cause inform cure? Mol Psychiatry 13:1070-1078.
45. Verhafen M, Van der Meij A, Van Deurzen P, Janzing JGE, Arias-Vasquez A, Buitelaar JK, et al. (2008). Meta-analysis of BDNF Val66Met polymorphisms in major depressive disorder: effects of gender and ethnicity. Mol Psychiatry 1:1-12.
46. Wang JW, Dranovsky A, Hen R (2008a). The when and where of BDNF and the antidepressant response. Biol Psychiatry 63:640-641.
47. Wang JW, Dranovsky A, Monckton JE, Battaglia F, Hen R (2008b). Chronic fluoxetine stimulates maturation and synaptic plasticity of adult-born hippocampal granule cells. J Neurosci 28:1374-1384.
48. Wray NR, James MR, Handoko HY, Dumenil T, Lind PA, Montgomery GW, Martin NG (2008). Association study of candidate variants from a brain-derived neurotrophic factor and dystrobrevin-binding protein 1 with neuroti-cism, anxiety and depression. Psychiatr Genet 18:219-225.